Charles Schwab
TNGX icon

Charles Schwab’s Tango Therapeutics TNGX Stock Holding History

Charles Schwab’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$33.5M Buy
1,072,059
+233,384
+28% +$5.77M ﹤0.01% 1505
2026
Q1 		$17.5M Sell
838,675
-2,317
-0.3% -$32.3K ﹤0.01% 1812
2025
Q4 		$7.45M Buy
840,992
+182,700
+28% +$1.57M ﹤0.01% 2272
2025
Q3 		$5.53M Buy
658,292
+56,845
+9% +$385K ﹤0.01% 2394
2025
Q2 		$3.08M Buy
601,447
+53,433
+10% +$132K ﹤0.01% 2525
2025
Q1 		$751K Buy
548,014
+34,585
+7% +$84.9K ﹤0.01% 2944
2024
Q4 		$1.59M Buy
513,429
+26,192
+5% +$122K ﹤0.01% 2747
2024
Q3 		$3.75M Buy
487,237
+76,540
+19% +$730K ﹤0.01% 2507
2024
Q2 		$3.52M Buy
410,697
+31,220
+8% +$241K ﹤0.01% 2513
2024
Q1 		$3.01M Buy
379,477
+10,411
+3% +$112K ﹤0.01% 2475
2023
Q4 		$3.65M Buy
369,066
+1,709
+0.5% +$14.8K ﹤0.01% 2441
2023
Q3 		$4.14M Buy
367,357
+247,234
+206% +$1.51M ﹤0.01% 2339
2023
Q2 		$399K Sell
120,123
-3,734
-3% -$13.4K ﹤0.01% 3152
2023
Q1 		$489K Hold
123,857
– – ﹤0.01% 2959
2022
Q4 		$898K Sell
123,857
-3,252
-3% -$22.9K ﹤0.01% 2808
2022
Q3 		$461K Buy
127,109
+331
+0.3% +$1.41K ﹤0.01% 3027
2022
Q2 		$575K Buy
126,778
+102,467
+421% +$620K ﹤0.01% 3021
2022
Q1 		$185K Hold
24,311
– – ﹤0.01% 3320
2021
Q4 		$266K Hold
24,311
– – ﹤0.01% 3306
2021
Q3 		$315K Buy
+24,311
New +$291K ﹤0.01% 3256

Other funds holding TNGX

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Charles Schwab's TNGX Position: Q2 2026 in Review

Charles Schwab increased its Tango Therapeutics (TNGX) stake by 28% in Q2 2026, buying an estimated $5.77M and bringing the position to 1,072,059 shares worth $33.5M. The position accounts for ﹤0.01% of the portfolio, ranked #1505.

Charles Schwab first reported a position in TNGX in Q3 2021 and has held it in 20 quarters since. 248 funds tracked by Wall St. Rank hold TNGX as of Q2 2026.

  • Charles Schwab held 1,072,059 shares of Tango Therapeutics worth $33.5M as of Q2 2026.
  • Charles Schwab bought 233,384 Tango Therapeutics shares in Q2 2026, an estimated $5.77M.
  • Tango Therapeutics made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #1505 holding.
  • Charles Schwab first reported a position in Tango Therapeutics in Q3 2021 and has held it in 20 quarters since.
  • 248 funds tracked by Wall St. Rank held Tango Therapeutics as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.